Results 121 to 130 of about 68,651 (161)

Metabolic plasticity in pancreatic ductal adenocarcinoma progression and response to treatment. [PDF]

Mol Cancer
Ma J, Bhardwaj V, Lobie PE, Pandey V.
europepmc   +1 more source

Molecular Pathology of Pancreatic Ductal Adenocarcinoma. [PDF]

Cancers (Basel)
Shalaby A, Sadri N, Xue Y.
europepmc   +1 more source

Syndecans and Pancreatic Ductal Adenocarcinoma [PDF]

Biomolecules, 2021
Pancreatic Ductal Adenocarcinoma (PDAC) is a fatal disease with poor prognosis because patients rarely express symptoms in initial stages, which prevents early detection and diagnosis. Syndecans, a subfamily of proteoglycans, are involved in many physiological processes including cell proliferation, adhesion, and migration.
Nausika Betriu, CARLOS Semino, Semino CARLOS E   +2 more
exaly   +5 more sources

Some of the next articles are maybe not open access.

Related searches:

Immunotherapy for pancreatic ductal adenocarcinoma

Journal of Surgical Oncology, 2021
AbstractPancreatic ductal adenocarcinoma (PDAC) remains a lethal cancer with an urgent need for better medical therapies. Efforts have been made to investigate the efficacy of immunotherapy, particularly given the hallmarks of immune suppression and exhaustion in PDAC tumors.
Eileen Carpenter, Sarah Nelson, Filip Bednar, Clifford Cho, Hari Nathan, Vaibhav Sahai, Marina Pasca di Magliano, Timothy L. Frankel   +7 more
openaire   +2 more sources

Microbiome and pancreatic ductal adenocarcinoma

Clinics and Research in Hepatology and Gastroenterology, 2021
Pancreatic ductal adenocarcinoma (PDAC) incidence and related-deaths are increasing worldwide. PDAC is characterized by poor prognosis due to late diagnosis, high metastatic capacity and resistance to therapy. This is partially due to its specific microenvironment, where the stroma is prominent over tumor cells. Besides the oral and gut microbiota, the
Annemilaï Tijeras-Raballand, Marc Hilmi, Lucile Astorgues-Xerri, Rémy Nicolle, Ivan Bièche, Cindy Neuzillet   +5 more
openaire   +2 more sources

Aquaporins in pancreatic ductal adenocarcinoma

APMIS, 2021
Aquaporins are water channel proteins facilitating passive transport of water across cellular membranes. Aquaporins are over‐ or ectopically expressed in a multitude of cancers, including pancreatic ductal adenocarcinoma, which is a highly aggressive cancer with low survival rate. Evidence suggests that aquaporins can affect multiple cellular processes
Anne Sofie, Bruun-Sørensen, Sarannya, Edamana, Frédéric H, Login, Signe, Borgquist, Lene N, Nejsum   +4 more
openaire   +2 more sources

Hypoxia and pancreatic ductal adenocarcinoma

Cancer Letters, 2020
Chemotherapy and immunotherapy for pancreatic ductal adenocarcinoma (PDAC) have limited success. One reason for this is thought to be the cancer microenvironment surrounding PDAC. Hypoxia is a feature of the cancer microenvironment. Under hypoxia, different various molecules and signaling pathways are activated compared with normoxia.
Akio, Yamasaki, Kosuke, Yanai, Hideya, Onishi   +2 more
openaire   +2 more sources

Genomics of pancreatic ductal adenocarcinoma

Hepatobiliary & Pancreatic Diseases International, 2014
Pancreatic cancer is one of the worst prognostic cancers because of the late diagnosis and the absence of effective treatment. Within all subtypes of this disease, ductal adenocarcinoma has the shortest survival time. In recent years, global genomics profiling allowed the identification of hundreds of genes that are perturbed in pancreatic cancer.
Christian, Pilarsky, Robert, Grutzmann
openaire   +2 more sources

Biomarkers in pancreatic ductal adenocarcinoma

Clinical and Translational Oncology, 2017
Pancreatic ductal adenocarcinoma (PDAC) is currently the third most frequent form of malignancy. The role of biomarkers in the diagnostic and therapeutic strategy of cancer is constantly expanding. Translational research is already changing paradigms in tumours encompassing from early diagnosis to precision medicine in advanced disease.
J. Gallego, C. López, R. Pazo-Cid, F. López-Ríos, A. Carrato   +4 more
openaire   +2 more sources

Surgery for pancreatic ductal adenocarcinoma

Clinical and Translational Oncology, 2017
Surgical resection is the only potentially curative option in the treatment of pancreatic ductal adenocarcinoma. Preoperative radiological imaging allows to rule out the presence of metastases. Three resectability categories are established based on the radiological findings depending on the degree of contact between the tumor and the blood vessels ...
R. Vera, L. Díez, E. Martín Pérez, J. C. Plaza, A. Sanjuanbenito, A. Carrato   +5 more
openaire   +2 more sources